Analysis of the policies, incentives, and market dynamics shaping pharmacy and healthcare.
Business models, ownership structures, and channel strategies mapped as one framework — PBM-owned, health-plan-owned, health-system, retail, mail, manufacturer, independent, 340B, and niche.
Lower list prices will not guarantee better access. PBMs will not work for free. Plan sponsors will not cover every treatment. The uncomfortable realities behind reform.
Five plays employers can run to protect against 340B leakage — fix the PBM contract, control the pharmacy network, optimize the formulary, avoid shared savings, and track the right metrics.
From full coverage to never-cover, six distinct employer archetypes are shaping GLP-1 access. Each requires a different strategic response.
Insulin dominates the debate, but GLP-1s, oncology, autoimmune, dermatologicals, migraine, and MS carry equally severe out-of-pocket burdens. Here is the iceberg beneath the headlines.
